Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda

Joseph Sempa, Mark Ssennono, Andreas Kuznik, Mohammed Lamorde, Stefanie Sowinski, Aggrey Semeere, Sabine Hermans, Barbara Castelnuovo, Yukari C Manabe

Research output: Contribution to journalArticle


Background: Ugandan national guidelines recommend initiation of combination antiretroviral therapy (cART) at CD4 + T cell (CD4) count below 350 cell/l, but the implementation of this is limited due to availability of medication. However, cART initiation at higher CD4 count increases survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250-350 cell/l (early) versus

Original languageEnglish (US)
Article number736
JournalBMC Public Health
Issue number1
Publication statusPublished - 2012



  • Adverse effects
  • Economics
  • Mortality

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this